Priaxon AG

https://www.priaxon.com

Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. The goal is to discover and develop candidates for validated but hard-to-drug targets using two orthogonal drug discovery platforms. *

	Start	2008-01-01 established
	Predecessor	Priaton GmbH
	Industry	drug discovery
	Industry 2	small-molecule drug
	Person	Burdack, Christoph (Priaxon AG 201401 CEO)
	Person 2	Höfer, Constance (Priaxon 201401– Chief Development Officer before Medigene + Merck KGaA + Solvay)

	Region	München (Munich)
	Country	Germany
	Street	37–37a Gmunder Str.
	City	81379 München
	Tel	+49-89-4521308-0
		Address record changed: 2020-12-02

Basic data	Employees	A: 1 to 10 (2014-11-08)

		* Document for »About Section«:

		Record changed: 2023-12-30

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)